Northwest Biotherapeutics, Inc. (NWBO) Launches Cross-country Enrollment for Promising Brain Cancer Treatment

QualityStocks would like to highlight Northwest Biotherapeutics (OTCBB: NWBO), a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.

In the company’s news yesterday,

Northwest Biotherapeutics announced it has begun enrollment of new patients in the company’s ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most fatal type of brain cancer.

So far the company has enrolled 33 patients for the cancer trial and its information arm; patients are already receiving treatment regimen and follow-up.

Four recruiting centers are carrying out the company’s enrollment initiatives: the University of Rochester in New York; the University Hospitals of Cleveland in Ohio; the Henry Ford Health System in Michigan; and the Virginia Piper Cancer Center of the University of Minnesota.

In addition, another eight medical centers across the nation are making reparations to conduct additional enrollment in the ongoing GBM trial, four of which are expected to begin or resume recruiting and screening during this quarter.

“We are pleased to have medical centers spread across the U.S. which are ramping up additional enrollment into our ongoing GBM brain cancer clinical trial,” Dr. Alton Boynton, CEO of NWBT stated in the press release. “This will help patients participate in the trial without having to travel too far, and it will also help us accelerate the overall enrollment required for completion of the trial.”

NWBT reported positive results in prior clinical trials of DCVax for patients with GBM brain cancer, demonstrating that the patients who received DCVax showed a median survival of three years, compared with median survival of only 14.6 months with standard of care today (surgery, radiation and chemotherapy). In addition, patients treated with DCVax did not have their tumor recur for approximately two years, on average, as compared with tumor recurrence in seven months with standard of care today. The company also reported that patients treated with DCVax did not experience any toxic side effects, such as those found with chemotherapy treatment.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.